Latest TCRR reports update at 2023-05-11: 2023-Q1 ∙ 2022-Q4 ∙ 2022-Q1

TCR2 Therapeutics TCRR

$ 1.48 0.0%

TCR2 Therapeutics Financial Statements 2011-2024 | TCRR

Annual Financial Statements TCR2 Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	57.9 M	127 M	781 M	316 M	-	-	-	-	-	-	-	-
Shares	38.6 M	37.9 M	30.3 M	21.1 M	-	-	-	-	-	-	-	-
Historical Prices	1.5	3.34	25.7	14.7	-	-	-	-	-	-	-	-
Net Income	-152 M	-99.8 M	-67.1 M	-47.6 M	-24.3 M	-13.1 M	-9.92 M	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-153 M	-99.7 M	-68.7 M	-51.4 M	-26.5 M	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-150 M	-96.9 M	-67.1 M	-50.5 M	-26 M	-12.9 M	-9.71 M	-	-	-	-	-
Operating Expenses	153 M	99.7 M	68.7 M	51.4 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	24.4 M	22.5 M	16.7 M	13.9 M	6.78 M	3.61 M	2.26 M	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement TCR2 Therapeutics

	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	39.2 M	39.2 M	38.6 M	38.6 M	38.5 M	38.5 M	38.2 M	38.2 M	37.1 M	33.4 M	30.3 M	24.1 M	24 M	24 M	23.9 M	23.8 M	12.3 M	704 K	660 K	620 K	513 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-40.4 M	-	-30.6 M	-31.6 M	-29.1 M	-	-26.2 M	-24.3 M	-21.5 M	-18.5 M	-16.9 M	-16.2 M	-15.5 M	-12.8 M	-13.8 M	-11.1 M	-9.9 M	-7.69 M	-6.39 M	-6.19 M	-3.99 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-41.5 M	-	-31.1 M	-31.8 M	-29.2 M	-	-26.2 M	-24.3 M	-21.6 M	-18.6 M	-17.2 M	-16.7 M	-16.2 M	-13.6 M	-14.9 M	-12.1 M	-10.8 M	-8.44 M	-7.09 M	-6.81 M	-4.11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-40.9 M	-	-28.8 M	-30.4 M	-28.5 M	-	-24.3 M	-23.1 M	-21.1 M	-18.6 M	-16.1 M	-16 M	-15.9 M	-13.6 M	-14.3 M	-11.8 M	-10.6 M	-8.44 M	-6.79 M	-6.62 M	-4.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	41.5 M	-	31.1 M	31.8 M	29.2 M	-	26.2 M	24.3 M	21.6 M	18.6 M	17.2 M	16.7 M	16.2 M	13.6 M	14.9 M	12.1 M	10.8 M	8.44 M	7.09 M	6.81 M	4.11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	8.2 M	-	6.31 M	6 M	6.32 M	-	5.96 M	5.67 M	5.67 M	4.27 M	4.37 M	3.81 M	4.27 M	4.18 M	3.52 M	3.31 M	2.89 M	2.22 M	1.7 M	1.63 M	1.22 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency